Skip to main content

Table 2 Hazard ratios with 95% confidence intervals and levels of significance for stopping treatment

From: Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden

All reasons HR (95% CI) Level of significance
Unadjusted infliximab vs. etanercept 2.37 (1.91; 2.93) p < 0.001
aInfliximab vs. etanercept 2.92 (2.32; 3.69) p < 0.001
bMonotherapy vs. MTX 1.82 (1.45; 2.29) p < 0.001
bOther DMARD vs. MTX 1.45 (1.12; 1.87) p < 0.010
bMonotherapy vs. other DMARD 1.22 (0.94; 1.61) p = 0.127
All reasons, time-dependent Cox regression analysis HR (95% CI) Level of significance
aInfliximab vs. etanercept 2.83 (2.27; 3.54) p < 0.001
bMonotherapy vs. MTX 1.48 (1.19; 1.85) p < 0.001
bOther DMARD vs. MTX 1.33 (1.08; 1.55) p = 0.017
bMonotherapy vs. other DMARD 1.10 (0.86; 1.40) p = 0.448
Adverse events HR (95% CI) Level of significance
bMonotherapy vs. MTX 2.14 (1.61; 2.84) p < 0.001
bOther DMARD vs. MTX 1.75 (1.28; 2.04) p = 0.001
bMonotherapy vs. other DMARD 1.23 (0.88; 1.71) p = 0.231
Treatment failure HR (95% CI) Level of significance
bMonotherapy vs. MTX 1.31 (0.86; 1.99) p = 0.215
bOther DMARD vs. MTX 1.07 (0.66; 1.73) p = 0.782
bMonotherapy vs. other DMARD 1.22 (0.72; 2.06) p = 0.454
  1. aAlso adjusted for differences in concomitant disease-modifying antirheumatic drugs (DMARDs). bAlso adjusted for differences in tumour necrosis factor-blocking treatment. The first row contains unadjusted data, whereas the remaining data were adjusted for differences in age, gender, year of treatment initiation, 28-joint disease activity score (DAS28), health assessment questionnaire (HAQ) score, disease duration, previous DMARDs, and C-reactive protein (CRP) level. Data presented in the second section use HAQ score, DAS28, and CRP level as time-dependent covariates. CI, confidence interval; HR, hazard ratio; MTX, methotrexate.